Bacil Pharma has received a regulatory disclosure from Khem-Sum Apparels Overseas Ltd. regarding the complete disposal of its shareholding under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction was completed on December 29, 2025, through an off-market sale.

Transaction Details

Khem-Sum Apparels Overseas Ltd., identified as a promoter group entity, has disposed of its entire holding in Bacil Pharma Limited. The disposal involved 200 equity shares, representing a minimal 0.001% stake in the company's total share capital.

Shareholding Pattern Changes

The disposal has resulted in a complete exit of Khem-Sum Apparels from Bacil Pharma's shareholding structure. The company's stake has been reduced from 0.001% to zero following this transaction.

Company Information

Bacil Pharma Limited's equity shares are listed on the Bombay Stock Exchange. The company maintains a total equity share capital of 14,353,000 equity shares of ₹10.00 each, which remains unchanged following this transaction.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was signed by Prakash Shah, Director of Khem-Sum Apparels Overseas Ltd. (DIN: 01136800), and submitted on December 30, 2025.

This transaction represents a complete divestment by the promoter group entity from its minimal shareholding in the pharmaceutical company, marking the end of Khem-Sum Apparels' investment in Bacil Pharma Limited.

Bacil Pharma Limited has received a substantial disposal disclosure from promoter Suman P. Shah under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, dated December 26, 2025. The disclosure pertains to the sale of equity shares by the promoter through market transactions.

Transaction Details

The disposal involved the sale of 500 equity shares by Suman P. Shah, who is classified as a promoter of the company. The transaction was executed through market sale on December 24, 2025.

Shareholding Pattern Changes

The disclosure reveals the complete disposal of Suman P. Shah's shareholding in Bacil Pharma Limited. Prior to this transaction, he held 500 equity shares, representing 0.00% of the total share capital. Following the sale, his shareholding has been reduced to zero.

Company Share Capital Structure

Bacil Pharma Limited's equity share capital structure remains unchanged following this transaction. The company maintains its total equity base with shares listed on the Bombay Stock Exchange.

The disclosure indicates that no encumbrances, voting rights other than equity shares, or convertible securities were involved in this transaction. The seller had no persons acting in concert (PAC) associated with this disposal. This regulatory filing ensures transparency in promoter shareholding changes and compliance with SEBI disclosure requirements for substantial acquisitions and disposals.